With regard to cancer development, SPARC has been described as a tumorsuppressor in some tumor types (e.g., in ovarian or bladder cancer [5,6]), while it was found overexpressed as a possible promoter of tumorigenesis in others (melanoma, breast cancer, and glioblastoma [7,8,9,10]). Here, SPARC is linked to melanoma.